CAMBRIDGE, Mass.–(BUSINESS WIRE)–BioAxone BioSciences, Inc., a biotechnology company focused on developing innovative drugs to treat neurotrauma and neurovascular disorders today announced that CEO Lisa McKerracher, PhD, will be a platform speaker on the Scientific Program, “Update on Clinical Trials in SCI” at NeuroTrauma2018, The 3rd Joint Symposium of the International and National […]
Other News
Arrowhead Pharmaceuticals Earns $10 Million Milestone Payment from Amgen
PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has earned a $10 million milestone payment from Amgen following the administration of the first dose of AMG 890, formerly referred to as ARO-LPA, in a clinical study. Amgen is evaluating AMG 890 in a Phase 1 clinical study […]
BioSig Technologies Files Application to Uplist to the NASDAQ
Santa Monica, CA, Aug. 01, 2018 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, announced that it has applied to list the Company’s common stock on […]
Amarin Reports Second Quarter 2018 Financial Results and Provides Update on Operations
BEDMINSTER, N.J., and DUBLIN, Ireland, Aug. 01, 2018 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the three and six months ended June 30, 2018, and provided an update on company operations. Key […]
John Radcliffe Oxford University Hospital is the First Medical Center in the UK to Use VEST Technology in Patients Undergoing Coronary Bypass Surgery
TEL AVIV, Israel, Aug. 1, 2018 /PRNewswire/ — Vascular Graft Solutions announces today that John Radcliffe hospital in Oxford, is the first center in the UK to use its VEST technology to externally support vein grafts in patients undergoing coronary bypass surgery. “After several decades in which little progress had been made in coronary […]
LivaNova Reports Second Quarter 2018 Results
LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2018. For the second quarter of 2018, worldwide sales from continuing operations were $287.5 million, an increase of 12.4 percent on a reported basis and an increase of 10.2 percent on […]
Infraredx Announces Launch of Makoto™ Intravascular Imaging System and Dualpro™ IVUS+NIRS Catheter in Japan
BURLINGTON, Mass.–(BUSINESS WIRE)–Infraredx, Inc., a pioneer in intravascular imaging for mapping coronary artery disease, today announced the Makoto™ Intravascular Imaging System, and accompanying Dualpro™ intravascular ultrasound and near-infrared spectroscopy (IVUS+NIRS) catheter, is now available in Japan. The launch follows a successful Spring 2018 limited market release, which included more than […]
Cerenis Announces Today the Appointment of Barbara Yanni to Its Board of Directors as an Independent Director
TOULOUSE, France & LAKELAND, Mich.–(BUSINESS WIRE)–Regulatory News: Cerenis Therapeutics (FR0012616852 – CEREN – PEA PME eligible), an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies for treating cardiovascular, metabolic diseases, and new HDL-based vectors for the targeted drug delivery in the oncology field announces today the […]
GE Healthcare and Lantheus Announce Start of a Phase 3 Clinical Trial of Flurpiridaz, an Investigational Agent Being Evaluated for the Detection of Coronary Artery Disease
BOSTON & NORTH BILLERICA, Mass.–(BUSINESS WIRE)–GE Healthcare and Lantheus Holdings, Inc. (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. (collectively “Lantheus”), have started a second Phase 3 clinical trial of Flurpiridaz 18F (called the AURORA study), an investigational agent being evaluated for the detection of coronary artery disease (CAD), the […]
Thermedical Announces FDA Investigational Device Exemption Approval to Begin US Clinical Study of Durablate Catheter for Treatment of Ventricular Tachycardia
WALTHAM, Mass.–(BUSINESS WIRE)–Thermedical® announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application for the Early Feasibility Study (EFS) of the groundbreaking Durablate™ ablation catheter. The single-arm, observational study is designed to evaluate the safety and effectiveness of the Durablate catheter to […]